Elevar Therapeutic’s rivoceranib trial has potential to treat late-stage gastric cancer patients, study says

Elevar Therapeutics presented a study at ESMO, showing the potential of rivoceranib to treat patients with late-stage gastric cancer, which was is the first multinational phase 3 study after rivoceranib’s approval in China, said Dr. Steven Norton, Elevar Therapeutics’ Vice President of Clinical Development.

Read more